Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear. 
Gemcitabine
Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear.  The aim of this study was to investigate the evidence of the role of adjuvant GEM therapy on survival in resected pancreatic cancer.  Four phase III randomized trials of adjuvant GEM in patients with resected pancreatic cancer were identified and the hazard ratio (HR) for overall survival were used in this meta-analysis; 2 studies compared GEM treatment with best supportive care and 2 studies with 5-fluorouracil/folinic acid therapy.  The combined HR significantly favors GEM over the other treatments.  The results indicate that GEM prolongs overall survival compared with other treatments after the resection of pancreatic cancer.
GEM
Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.Gemcitabine (GEM) is an approved treatment for unresectable pancreatic cancer; however, its role in treating resected pancreatic cancer is less clear.  Four phase III randomized trials of adjuvant GEM in patients with resected pancreatic cancer were identified and the hazard ratio (HR) for overall survival were used in this meta-analysis; 2 studies compared GEM treatment with best supportive care and 2 studies with 5-fluorouracil/folinic acid therapy. 
Meta-analysis